Pfizer Shares Rise After AstraZeneca Plunges 8% on Heart Drug Failure
PFE•Pfizer shares rose following an 8% drop in AstraZeneca’s stock after its partner Ionis announced a Phase III heart drug failure. Rival Alnylam shares surged as Ionis stock tumbled, reflecting rotation into Pfizer and other contenders.
1. Pfizer Stock Reaction
Pfizer shares climbed in early trading as investors shifted funds into perceived safer or outperforming biotechs after a major sector setback. The uptick underscores Pfizer’s role as a leading competitor benefiting from volatility among peers.
2. AstraZeneca Trial Failure
AstraZeneca experienced an 8% share decline when its Phase III cardiovascular candidate failed to meet primary endpoints, surprising markets and triggering a sell-off in related stocks.
3. Partner Ionis Slides
Ionis Pharmaceuticals, the development partner on the failed heart drug, saw its stock slump sharply as analysts reassessed the impact of the trial setback on its pipeline and revenue forecasts.
4. Rival Biotechs Surge
Investors rotated into rivals, lifting Pfizer and sending Alnylam shares higher. Alnylam marked a notable double-digit gain as funds flowed from fallen sector names into companies with stronger near-term catalysts.
